Galina S. Alekseeva
Research Subjects
Galina S. Alekseeva has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Guzal R. Abuzarova
P. A. Hertsen Moscow Oncology Research Institute – a branch of the National Medical Research Centre for Radiology of the Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia
8 shared publications - Andrei Dmitrievich Kaprin
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Koroleva St. 4, 249036 Obninsk, Russia
5 shared publications - Regina R. Sarmanayeva
P. A. Hertsen Moscow Oncology Research Institute – a branch of the National Medical Research Centre for Radiology of the Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia
5 shared publications - Elena Vladimirovna Gameeva
Federal State Budgetary Institution «National Medical Research Center for Rehabilitation and Balneology» of the Ministry of Health of the Russian Federation, Moscow, Russia
4 shared publications - Victoria E. Khoronenko
P.A. Hertsen Moscow Oncology Research Center, Moscow, Russia; RUDN University, Moscow, Russia
4 shared publications - S. V. Kuznetcov
P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia
3 shared publications
Latest Publications
- 15 October 2026
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 5
Opioid-sparing strategies for postoperative pain management in cancer patients with chronic pain syndrome undergoing spine fusion surgery
Postoperative analgesia in cancer patients with chronic pain syndrome (CPS) undergoing spine fusion surgery remains a complex clinical challenge due to multifactorial nature of pain and the risk of increased opioid burden. Objective. To summarize literature data on multimodal postoperative analgesia in cancer patients with emphasis on opioid-sparing approaches and infusion forms of non-steroidal anti-inflammatory drugs (NSAIDs). Material and methods. A narrative review with elements of systematic searching was performed using the PubMed and eLibrary databases. Results. Studies addressing CPS in malignant diseases, pain associated with metastatic spinal lesions and postoperative analgesia in spinal surgery including intravenous ibuprofen and a fixed combination of diclofenac with orphenadrine were analyzed. Literature data indicate that postoperative pain in these patients can include nociceptive, inflammatory, neuropathic, and muscle-tonic components. Conclusion. Infusion of NSAIDs is reasonable for multimodal opioid-sparing analgesic regimens. However, their efficacy and safety in cancer patients with CPS require further investigation.
- 15 October 2026
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 5
Opioid-sparing strategies for postoperative pain management in cancer patients with chronic pain syndrome undergoing spine fusion surgery
Postoperative analgesia in cancer patients with chronic pain syndrome (CPS) undergoing spine fusion surgery remains a complex clinical challenge due to multifactorial nature of pain and the risk of increased opioid burden. Objective. To summarize literature data on multimodal postoperative analgesia in cancer patients with emphasis on opioid-sparing approaches and infusion forms of non-steroidal anti-inflammatory drugs (NSAIDs). Material and methods. A narrative review with elements of systematic searching was performed using the PubMed and eLibrary databases. Results. Studies addressing CPS in malignant diseases, pain associated with metastatic spinal lesions and postoperative analgesia in spinal surgery including intravenous ibuprofen and a fixed combination of diclofenac with orphenadrine were analyzed. Literature data indicate that postoperative pain in these patients can include nociceptive, inflammatory, neuropathic, and muscle-tonic components. Conclusion. Infusion of NSAIDs is reasonable for multimodal opioid-sparing analgesic regimens. However, their efficacy and safety in cancer patients with CPS require further investigation.
- 16 June 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (3) , 13-21
Efficacy and safety of Tafalgin in palliative patients with chronic pain: results of a multicenter NIKITA-P study
Objective. To evaluate the efficacy and safety of the peptide analgesic Tafalgin in palliative patients with chronic pain syndrome. Material and methods. A multicenter (19 centers) non-interventional clinical trial of NIKITA-Palliative was conducted in 188 patients, mainly with oncological (84.5%) chronic pain syndrome (CPS) and comorbid pathology. Results. The initial pain intensity (IP) was 7.18—8.11 NRS points (from 0 to 10), 15 minutes after injection there was a statistically significant decrease in pain at rest and during movement (p<0.0001); after 1 hour, IP decreased below the level of <3 points. Maximal analgesic effect was achieved after an average of 45 minutes, and the duration of anesthesia was 8.5 hours. The proportion of patients who responded to Tafalgin therapy was 94.1%, and 72.3% of patients achieved a sufficient level of anesthesia. During treatment, there was a statistically significant improvement in quality of life: a decrease in general weakness, irritability, daytime sleepiness, an improvement in nighttime sleep and appetite (p<0.0001), and an improvement in the quality of nighttime sleep. The majority of doctors (69.7%) and patients (66.6%) rated the effectiveness of Tafalgin therapy as good or excellent. Adverse reactions (AR) were reported in 14 of 188 patients (7.4%), with a total of 26 AR. The most common were blurred consciousness (2.6%), dizziness (2.1%) and dry mouth (1.6%). All AR were mild or moderate, no serious adverse reactions were recorded, and all episodes were treated without consequences. Conclusion. Tafalgin demonstrated an effective reduction in pain intensity lasting 8.5 hours against the background of a favorable safety profile in palliative patients with chronic pain syndrome despite concomitant pathology. The drug can be considered as an effective component of analgesic therapy of severe pain, including in combination with non-narcotic, narcotic and adjuvant analgesics.
- 16 June 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (3) , 13-21
Efficacy and safety of Tafalgin in palliative patients with chronic pain: results of a multicenter NIKITA-P study
Objective. To evaluate the efficacy and safety of the peptide analgesic Tafalgin in palliative patients with chronic pain syndrome. Material and methods. A multicenter (19 centers) non-interventional clinical trial of NIKITA-Palliative was conducted in 188 patients, mainly with oncological (84.5%) chronic pain syndrome (CPS) and comorbid pathology. Results. The initial pain intensity (IP) was 7.18—8.11 NRS points (from 0 to 10), 15 minutes after injection there was a statistically significant decrease in pain at rest and during movement (p<0.0001); after 1 hour, IP decreased below the level of <3 points. Maximal analgesic effect was achieved after an average of 45 minutes, and the duration of anesthesia was 8.5 hours. The proportion of patients who responded to Tafalgin therapy was 94.1%, and 72.3% of patients achieved a sufficient level of anesthesia. During treatment, there was a statistically significant improvement in quality of life: a decrease in general weakness, irritability, daytime sleepiness, an improvement in nighttime sleep and appetite (p<0.0001), and an improvement in the quality of nighttime sleep. The majority of doctors (69.7%) and patients (66.6%) rated the effectiveness of Tafalgin therapy as good or excellent. Adverse reactions (AR) were reported in 14 of 188 patients (7.4%), with a total of 26 AR. The most common were blurred consciousness (2.6%), dizziness (2.1%) and dry mouth (1.6%). All AR were mild or moderate, no serious adverse reactions were recorded, and all episodes were treated without consequences. Conclusion. Tafalgin demonstrated an effective reduction in pain intensity lasting 8.5 hours against the background of a favorable safety profile in palliative patients with chronic pain syndrome despite concomitant pathology. The drug can be considered as an effective component of analgesic therapy of severe pain, including in combination with non-narcotic, narcotic and adjuvant analgesics.
- 4 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 3
Fluorothiazinon in complex therapy of postoperative infectious-inflammatory complications
The problem of carbapenem-resistant gram-negative flora in intensive care units (ICUs) is a major challenge for modern critical care. Limitations and toxicity of modern therapeutic options create significant difficulties in management of critically ill patients. A promising alternative is a new domestic drug fluorothiazinon with unique mechanism of action aimed at suppressing virulence of microorganisms rather than their direct eradication. The authors present successful treatment of a patient with postoperative pneumonia, mediastinitis, pleural empyema, and septic shock caused by a strain of Klebsiella pneumoniae with the blaOXA-48-like gene. Therapy with meropenem (in high dose with extended infusion) and fluorothiazinon was followed by positive dynamics with hemodynamic stabilization, regression of organ dysfunction, and improvement of laboratory markers. The authors concluded high clinical efficacy and favorable safety of fluorothiazinon combined with carbapenem for the treatment of infections caused by carbapenem-resistant gram-negative flora. Potential niches for this drug are total or subtotal drug resistance, as well as the need for long-term suppressive therapy for chronic recurrent infections.
- 4 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 3
Fluorothiazinon in complex therapy of postoperative infectious-inflammatory complications
The problem of carbapenem-resistant gram-negative flora in intensive care units (ICUs) is a major challenge for modern critical care. Limitations and toxicity of modern therapeutic options create significant difficulties in management of critically ill patients. A promising alternative is a new domestic drug fluorothiazinon with unique mechanism of action aimed at suppressing virulence of microorganisms rather than their direct eradication. The authors present successful treatment of a patient with postoperative pneumonia, mediastinitis, pleural empyema, and septic shock caused by a strain of Klebsiella pneumoniae with the blaOXA-48-like gene. Therapy with meropenem (in high dose with extended infusion) and fluorothiazinon was followed by positive dynamics with hemodynamic stabilization, regression of organ dysfunction, and improvement of laboratory markers. The authors concluded high clinical efficacy and favorable safety of fluorothiazinon combined with carbapenem for the treatment of infections caused by carbapenem-resistant gram-negative flora. Potential niches for this drug are total or subtotal drug resistance, as well as the need for long-term suppressive therapy for chronic recurrent infections.
- 13 April 2026
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 1
Management of elderly patients with cancer. Expert consensus in geriatrics and oncology
Aging is the risk factor for developing cancer — approximately 60 % of cancer occurs in people 65 years or older. Treatment planning that takes into account the patient's geriatric status and preferences helps achieve better outcomes and patient satisfaction. Conducting a comprehensive geriatric assessment and developing an individualized care plan during the preparation and treatment stages of cancer, as well as post-surgery, radiation therapy, and/or chemotherapy, helps reduce the risk of complications and maintain patients' quality of life. Due attention should be paid to prehabilitation tools, which focus on improving the patient's physical condition, optimizing nutrition, cognitive interventions, reducing stress and anxiety, and correcting anemia and other comorbidities. Measures included in prehabilitation programs have a synergistic effect: interventions that may not produce significant clinical results individually, when combined, provide significant improvements in the postoperative period. The lack of clinical trials in cancer patients aged 75 years and older is a common problem worldwide. The importance of a comprehensive multidisciplinary approach to managing these patients should be emphasized to improve overall survival, quality of life, and reduce the risk of potential complications.
- 13 April 2026
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 1
Management of elderly patients with cancer. Expert consensus in geriatrics and oncology
Aging is the risk factor for developing cancer — approximately 60 % of cancer occurs in people 65 years or older. Treatment planning that takes into account the patient's geriatric status and preferences helps achieve better outcomes and patient satisfaction. Conducting a comprehensive geriatric assessment and developing an individualized care plan during the preparation and treatment stages of cancer, as well as post-surgery, radiation therapy, and/or chemotherapy, helps reduce the risk of complications and maintain patients' quality of life. Due attention should be paid to prehabilitation tools, which focus on improving the patient's physical condition, optimizing nutrition, cognitive interventions, reducing stress and anxiety, and correcting anemia and other comorbidities. Measures included in prehabilitation programs have a synergistic effect: interventions that may not produce significant clinical results individually, when combined, provide significant improvements in the postoperative period. The lack of clinical trials in cancer patients aged 75 years and older is a common problem worldwide. The importance of a comprehensive multidisciplinary approach to managing these patients should be emphasized to improve overall survival, quality of life, and reduce the risk of potential complications.
- 11 December 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (4) , 8-21
Quality of life of patients with cervical and uterine cancer after radical treatment and rehabilitation options using hyaluronic acid-based volume-forming agents
Purpose of the study . To assess the quality of life in patients with cervical cancer (CC) and endometrial cancer (EC) after radical treatment and to evaluate the effectiveness of hyaluronic acid (HA)-based volumizing agents in correcting vulvovaginal atrophy (VVA). Patients and methods . The study included 201 patients with stage I–III CC and stage I–II EC (FIGO, 2018) after surgical (Group 1, 33.3 %), combined (Group 2, 37.3 %), or concurrent radiotherapy/chemoradiotherapy (Group 3, 29.4 %). Corrective therapy consisted of intravaginal and perineal administration of HA-based formulations according to the authors’ technique. Dynamic evaluation included vaginal transudate pH, Vaginal Health Index (VHI), and sexual function (PISQ‑12). Results . Following radical treatment, all patients demonstrated severe VVA, which was more pronounced in groups receiving radiotherapy either alone or as adjuvant treatment – vaginal pH 6.59 ± 0.6 and 6.43 ± 0.8, respectively, versus 6.05 ± 0.9 after surgery (p = 0.001 and p = 0.01). VHI was 7.7 ± 2.5 and 9.2 ± 3.7, respectively, compared with 11.1 ± 3.7 in the surgical group (p = 0.00001 and p = 0.02). After restorative therapy, improvements were noted as early as 1 month: in Group 1 – pH 5.2 ± 0.8 and VHI 17.3 ± 2.9; in Group 2 – pH 5.5 ± 0.6 and VHI 16.75 ± 3.0; in Group 3 – pH 5.4 ± 0.7 and VHI 16.7 ± 2.6 (all p < 0.00001, intergroup comparisons p > 0.05), with sustained effect over 12 months. Sexual function normalized: PISQ‑12 decreased from 15.9 ± 6.7 to 12.0 ± 5.0 and from 14.7 ± 6.0 to 12.0 ± 4.7 in Groups 1 and 3 at 1 month, while in Group 2 scores declined from 15.8 ± 4.9 to 9.5 ± 3.5 at later follow-ups (all p < 0.00001). Conclusion . Patients with CC and EC after radical treatment develop vaginal mucosal atrophy, more pronounced after radiotherapy. This condition can be effectively corrected using HA-based formulations.
- 11 December 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (4) , 8-21
Quality of life of patients with cervical and uterine cancer after radical treatment and rehabilitation options using hyaluronic acid-based volume-forming agents
Purpose of the study . To assess the quality of life in patients with cervical cancer (CC) and endometrial cancer (EC) after radical treatment and to evaluate the effectiveness of hyaluronic acid (HA)-based volumizing agents in correcting vulvovaginal atrophy (VVA). Patients and methods . The study included 201 patients with stage I–III CC and stage I–II EC (FIGO, 2018) after surgical (Group 1, 33.3 %), combined (Group 2, 37.3 %), or concurrent radiotherapy/chemoradiotherapy (Group 3, 29.4 %). Corrective therapy consisted of intravaginal and perineal administration of HA-based formulations according to the authors’ technique. Dynamic evaluation included vaginal transudate pH, Vaginal Health Index (VHI), and sexual function (PISQ‑12). Results . Following radical treatment, all patients demonstrated severe VVA, which was more pronounced in groups receiving radiotherapy either alone or as adjuvant treatment – vaginal pH 6.59 ± 0.6 and 6.43 ± 0.8, respectively, versus 6.05 ± 0.9 after surgery (p = 0.001 and p = 0.01). VHI was 7.7 ± 2.5 and 9.2 ± 3.7, respectively, compared with 11.1 ± 3.7 in the surgical group (p = 0.00001 and p = 0.02). After restorative therapy, improvements were noted as early as 1 month: in Group 1 – pH 5.2 ± 0.8 and VHI 17.3 ± 2.9; in Group 2 – pH 5.5 ± 0.6 and VHI 16.75 ± 3.0; in Group 3 – pH 5.4 ± 0.7 and VHI 16.7 ± 2.6 (all p < 0.00001, intergroup comparisons p > 0.05), with sustained effect over 12 months. Sexual function normalized: PISQ‑12 decreased from 15.9 ± 6.7 to 12.0 ± 5.0 and from 14.7 ± 6.0 to 12.0 ± 4.7 in Groups 1 and 3 at 1 month, while in Group 2 scores declined from 15.8 ± 4.9 to 9.5 ± 3.5 at later follow-ups (all p < 0.00001). Conclusion . Patients with CC and EC after radical treatment develop vaginal mucosal atrophy, more pronounced after radiotherapy. This condition can be effectively corrected using HA-based formulations.
- Open Access
- 1 August 2024
- Published by ECO-Vector LLC in Regional Anesthesia and Acute Pain Management
- Vol. 18 (2) , 115-131
Potential of modern nonopioid analgesics in the prevention and treatment of pain syndrome in decompressive stabilizing spine surgeries
BACKGROUND: Secondary (tumor) lesion of the spine in 80% of cases is accompanied by chronic pain syndrome (CPS). A decrease in opioid subsidies in the postoperative period is important not only to prevent side effects, but also in order to create a reserve when providing palliative care for patients with CP, due to the pathology of the skeletal muscle system. AIM: To optimize postop analgesia for cancer patients with CPS undergoing decompressive-stabilizing spine surgery. MATERIALS AND METHODS: We included 52 patients aged 32–76 (average age: 59±10 [95% CI: 56–62]) years, 23 (44.2%) men and 29 (55.8%) women, with physical status according to the classification of patients of the American Society of Anesthesiologists I–III, CPS without therapy were included strong opioids for spinal metastases. Patients were randomized according to the type of postop analgesia: tramadol was used in the control group (group K) (n=15, 28.8%), a combination of diclofenac and orphenadrine in group D (n=18, 34.6%), and ibuprofen in group I (n=19, 36.5%). Postoperative pain intensity deduced using the visual analog scale was determined during extubation, transfer to a bed in the intensive care unit, 1 and 3 hours postop, and 21:00 on the day of surgery and 06:00 on day 2. The effect duration of the analgesic under study, the need for anesthesia on the postop day, and satisfaction with Likert anesthesia 1 hour after administration were evaluated. RESULTS: Significant differences in the average values of pain intensity at rest at 06:00 on postoperative day 2 between groups D (Me=10) and K (Me=20) were obtained. Satisfaction with pain relief according to Likert scale in the groups was rated “excellent” or “good.” The duration of opioid therapy was significantly lower in the nonopioid groups (six postop days in groups I and D versus seven in group K; p=0.013). CONCLUSIONS: Postop analgesia methods using nonopioid analgesics are effective and possess opioid-sparing potential.
- 1 August 2024
- Published by ECO-Vector LLC in Regional Anesthesia and Acute Pain Management
- Vol. 18 (2) , 115-131
Open AccessPotential of modern nonopioid analgesics in the prevention and treatment of pain syndrome in decompressive stabilizing spine surgeries
BACKGROUND: Secondary (tumor) lesion of the spine in 80% of cases is accompanied by chronic pain syndrome (CPS). A decrease in opioid subsidies in the postoperative period is important not only to prevent side effects, but also in order to create a reserve when providing palliative care for patients with CP, due to the pathology of the skeletal muscle system. AIM: To optimize postop analgesia for cancer patients with CPS undergoing decompressive-stabilizing spine surgery. MATERIALS AND METHODS: We included 52 patients aged 32–76 (average age: 59±10 [95% CI: 56–62]) years, 23 (44.2%) men and 29 (55.8%) women, with physical status according to the classification of patients of the American Society of Anesthesiologists I–III, CPS without therapy were included strong opioids for spinal metastases. Patients were randomized according to the type of postop analgesia: tramadol was used in the control group (group K) (n=15, 28.8%), a combination of diclofenac and orphenadrine in group D (n=18, 34.6%), and ibuprofen in group I (n=19, 36.5%). Postoperative pain intensity deduced using the visual analog scale was determined during extubation, transfer to a bed in the intensive care unit, 1 and 3 hours postop, and 21:00 on the day of surgery and 06:00 on day 2. The effect duration of the analgesic under study, the need for anesthesia on the postop day, and satisfaction with Likert anesthesia 1 hour after administration were evaluated. RESULTS: Significant differences in the average values of pain intensity at rest at 06:00 on postoperative day 2 between groups D (Me=10) and K (Me=20) were obtained. Satisfaction with pain relief according to Likert scale in the groups was rated “excellent” or “good.” The duration of opioid therapy was significantly lower in the nonopioid groups (six postop days in groups I and D versus seven in group K; p=0.013). CONCLUSIONS: Postop analgesia methods using nonopioid analgesics are effective and possess opioid-sparing potential.
- Open Access
- 11 December 2023
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 13 (3) , 43-50
Orofacial pain in oncology: use of a new analgesic peptide tafalgin
In patients with head and neck tumors severe pain is more common than in patients with malignant neoplasms of other locations. At a third of patients, pain is the first characteristic of the disease, and after diagnosis, one half of the patients are already having pain syndrome. Аntitumor treatment often not only bring relief, but can intensify pain, which can reduce wish to treated. Part of cancer survivor continue to experience. Thus, orofacial pain syndrome should be share depending on the mechanism of appearence and tactics of treatment on three periods: pain at the stage of diagnosis, then pain syndrome in process antitumor therapy and pain in remission. It is actually if it necessary to prescribe opioid analgesics, especially for a long time. Intensity of orofacial pain syndrome is usually strong and often need to prescribe opioid analgesics. Option to opioid analgesics may be a representative of a new group of analgetics – peptide analgesics – tafalgin. The mechanism of action is due to highly selective agonism to the m1-opioid receptors. The presented clinical example demonstrates the good analgesic effect of tafalgin and the possibility use as option to analgesics of the second stage of pain management.
- 11 December 2023
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 13 (3) , 43-50
Open AccessOrofacial pain in oncology: use of a new analgesic peptide tafalgin
In patients with head and neck tumors severe pain is more common than in patients with malignant neoplasms of other locations. At a third of patients, pain is the first characteristic of the disease, and after diagnosis, one half of the patients are already having pain syndrome. Аntitumor treatment often not only bring relief, but can intensify pain, which can reduce wish to treated. Part of cancer survivor continue to experience. Thus, orofacial pain syndrome should be share depending on the mechanism of appearence and tactics of treatment on three periods: pain at the stage of diagnosis, then pain syndrome in process antitumor therapy and pain in remission. It is actually if it necessary to prescribe opioid analgesics, especially for a long time. Intensity of orofacial pain syndrome is usually strong and often need to prescribe opioid analgesics. Option to opioid analgesics may be a representative of a new group of analgetics – peptide analgesics – tafalgin. The mechanism of action is due to highly selective agonism to the m1-opioid receptors. The presented clinical example demonstrates the good analgesic effect of tafalgin and the possibility use as option to analgesics of the second stage of pain management.
- Open Access
- 25 November 2022
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 24 (3) , 313-318
A clinical case of the use of a new selective μ1-opioid analgesic Tafalgin in the treatment of chronic cancer pain
In the Russian Federation, tetrapeptide tyrosyl-D-arginyl-phenylalanyl-glycine amide (Tafalgin), a novel analgesic, selective agonist of 1-opioid receptors, was developed and approved in 2022. The article presents the first experience of the successful use of Tafalgin in treating chronic pain in a cancer patient with poor tolerance to traditional opioids (tramadol, tapentadol, morphine). At baseline, pain severity, according to the Neurological Rating Scale (NRS), was 57 points at rest and up to 9 points in motion out of the maximum 10. The combination of 400 mg/day of tramadol with gabapentin and a non-steroidal anti-inflammatory drug was ineffective; 400 mg/day of tapentadol in combination with gabapentin and a non-steroidal anti-inflammatory drug also was ineffective. Morphine tablets 60 mg/day were effective (NRS score of 23), but unrelenting nausea and vomiting were unmanageable and significantly reduced quality of life. Reducing the dose of oral morphine to 20 mg/day mitigated adverse events but reduced the effectiveness of pain relief (resting NRS score of 4 points). Tafalgin 4 mg subcutaneously BID, then TID reduced the pain severity to an average daily NRS score of 1.22 over the first 3 days of treatment with no adverse events. Sleep, appetite, and physical activity improved. The patient received Tafalgin for 84 days, and she gained 5 kg due to improved nutrition during that time. The drug is comparable in efficacy to morphine and is associated with fewer adverse events. A limitation to widespread use is the availability of a formulation for subcutaneous injection only.
- 25 November 2022
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 24 (3) , 313-318
Open AccessA clinical case of the use of a new selective μ1-opioid analgesic Tafalgin in the treatment of chronic cancer pain
In the Russian Federation, tetrapeptide tyrosyl-D-arginyl-phenylalanyl-glycine amide (Tafalgin), a novel analgesic, selective agonist of 1-opioid receptors, was developed and approved in 2022. The article presents the first experience of the successful use of Tafalgin in treating chronic pain in a cancer patient with poor tolerance to traditional opioids (tramadol, tapentadol, morphine). At baseline, pain severity, according to the Neurological Rating Scale (NRS), was 57 points at rest and up to 9 points in motion out of the maximum 10. The combination of 400 mg/day of tramadol with gabapentin and a non-steroidal anti-inflammatory drug was ineffective; 400 mg/day of tapentadol in combination with gabapentin and a non-steroidal anti-inflammatory drug also was ineffective. Morphine tablets 60 mg/day were effective (NRS score of 23), but unrelenting nausea and vomiting were unmanageable and significantly reduced quality of life. Reducing the dose of oral morphine to 20 mg/day mitigated adverse events but reduced the effectiveness of pain relief (resting NRS score of 4 points). Tafalgin 4 mg subcutaneously BID, then TID reduced the pain severity to an average daily NRS score of 1.22 over the first 3 days of treatment with no adverse events. Sleep, appetite, and physical activity improved. The patient received Tafalgin for 84 days, and she gained 5 kg due to improved nutrition during that time. The drug is comparable in efficacy to morphine and is associated with fewer adverse events. A limitation to widespread use is the availability of a formulation for subcutaneous injection only.
- Open Access
- 26 January 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (2) , 3164
Telehealth consultations in cardio-oncology
Aim . To evaluate the role of a cardiologist in telehealth counseling of cancer patients at the federal oncology center. Material and methods . This retrospective study was conducted based on the materials of 215 telehealth consultations on cardiooncology, performed in the period from January 2019 to September 2021. Data on referrals to a cardiologist (cardio-oncologist) from various Russian regions and consultants’ answers were analyzed, taking into account the following data: region, sex, age of a patient, cancer type, stage, participation of other consultants, type of cardiovascular disease, the need for additional information and features of treatment — surgery, chemotherapy, radiation therapy. Risk was stratified based on a checklist including the main risk factors for cardiotoxicity. The recommendations of consultants for monitoring patients, as well as drug therapy prescriptions, were analyzed. Results . The most common cancer sites in patients referred for telehealth consultations on cardio-oncology were lungs, larynx and trachea, colon and rectum, kidneys and bladder, ovaries and uterus, and stomach. Cardiologists consulted together with oncologists — surgeons, medical oncologists, as well as anesthesiologists and radiation oncologists. The most common cardiovascular diseases were hypertension — 80,9% of patients, heart failure — 60%, arrhythmias — 41,6% and coronary heart disease — 37,7%. From 71 to 80,3%, 15,6-21% and 3,9-7,8% of patients had preserved, mid-range and reduced left ventricular ejection fraction. In 47,6-66,7% of cases, consultants required additional information. Based on risk stratification of cardiotoxicity of anticancer treatment, 118 (81,9%) patients out of 144 were classified as high and very high risk. Most patients were recommended cardioprotective therapy, which most often included angiotensin-converting enzyme inhibitors/angiotensin receptor blockers — 43,1-53,1%, beta-blockers — 44,8-58,6%, and statins — 22,4-38,3%. An algorithm for creating a request for a cardio-oncology telehealth consultation has been developed. Conclusion . The important role of cardio-oncology telehealth consultations in the work of the federal oncology center is demonstrated. Consulting cardiologists are part of a single multidisciplinary team of specialists and must act taking into account the characteristics of cancer and antitumor therapy prescribed by oncologists.
- 26 January 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (2) , 3164
Open AccessTelehealth consultations in cardio-oncology
Aim . To evaluate the role of a cardiologist in telehealth counseling of cancer patients at the federal oncology center. Material and methods . This retrospective study was conducted based on the materials of 215 telehealth consultations on cardiooncology, performed in the period from January 2019 to September 2021. Data on referrals to a cardiologist (cardio-oncologist) from various Russian regions and consultants’ answers were analyzed, taking into account the following data: region, sex, age of a patient, cancer type, stage, participation of other consultants, type of cardiovascular disease, the need for additional information and features of treatment — surgery, chemotherapy, radiation therapy. Risk was stratified based on a checklist including the main risk factors for cardiotoxicity. The recommendations of consultants for monitoring patients, as well as drug therapy prescriptions, were analyzed. Results . The most common cancer sites in patients referred for telehealth consultations on cardio-oncology were lungs, larynx and trachea, colon and rectum, kidneys and bladder, ovaries and uterus, and stomach. Cardiologists consulted together with oncologists — surgeons, medical oncologists, as well as anesthesiologists and radiation oncologists. The most common cardiovascular diseases were hypertension — 80,9% of patients, heart failure — 60%, arrhythmias — 41,6% and coronary heart disease — 37,7%. From 71 to 80,3%, 15,6-21% and 3,9-7,8% of patients had preserved, mid-range and reduced left ventricular ejection fraction. In 47,6-66,7% of cases, consultants required additional information. Based on risk stratification of cardiotoxicity of anticancer treatment, 118 (81,9%) patients out of 144 were classified as high and very high risk. Most patients were recommended cardioprotective therapy, which most often included angiotensin-converting enzyme inhibitors/angiotensin receptor blockers — 43,1-53,1%, beta-blockers — 44,8-58,6%, and statins — 22,4-38,3%. An algorithm for creating a request for a cardio-oncology telehealth consultation has been developed. Conclusion . The important role of cardio-oncology telehealth consultations in the work of the federal oncology center is demonstrated. Consulting cardiologists are part of a single multidisciplinary team of specialists and must act taking into account the characteristics of cancer and antitumor therapy prescribed by oncologists.
- Open Access
- 26 October 2021
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 3
Assessment of xenon effect on postoperative pain syndrome severity in oncological patients: a randomized study
Introduction. The present study was designed to evaluate analgetic effect of xenon-oxygen mixture inhalations in oncological patients with abdominal tumors in postoperative period. Materials and methods. It was randomized blind placebo-controlled clinical trial, which was performed in 60 patients: 31 of them were in the main group and received xenon-oxygen mixture containing 25 ± 5 % xenon and other 29 were in the placebo group and received oxygen-air mixture. Results. According to the visual-analogical scale of pain, significant decreasing of the pain level was found in the main group after the inhalation and 30 minutes later in 90.3 % (p < 0.01) and 80.6 % of patients (p < 0.05) accordingly. The same result was found in the placebo group in 37.9 % of patients after oxygen-air mixture inhalation and 30 minutes later in 27.4 % of patients. The pain threshold measured with transcutaneal electroneurostimulation significantly increased in the xenon group after the inhalation (p < 0.01) and 30 minutes later (p < 0.05). In the placebo group no difference between the measurements was found. Conclusions. Xenon-oxygen mixture inhalation leads to the postoperative pain level reduction and increases the pain threshold in oncological patients.
- 26 October 2021
- Published by Practical Medicine Publishing House in Annals of Critical Care
- No. 3
Open AccessAssessment of xenon effect on postoperative pain syndrome severity in oncological patients: a randomized study
Introduction. The present study was designed to evaluate analgetic effect of xenon-oxygen mixture inhalations in oncological patients with abdominal tumors in postoperative period. Materials and methods. It was randomized blind placebo-controlled clinical trial, which was performed in 60 patients: 31 of them were in the main group and received xenon-oxygen mixture containing 25 ± 5 % xenon and other 29 were in the placebo group and received oxygen-air mixture. Results. According to the visual-analogical scale of pain, significant decreasing of the pain level was found in the main group after the inhalation and 30 minutes later in 90.3 % (p < 0.01) and 80.6 % of patients (p < 0.05) accordingly. The same result was found in the placebo group in 37.9 % of patients after oxygen-air mixture inhalation and 30 minutes later in 27.4 % of patients. The pain threshold measured with transcutaneal electroneurostimulation significantly increased in the xenon group after the inhalation (p < 0.01) and 30 minutes later (p < 0.05). In the placebo group no difference between the measurements was found. Conclusions. Xenon-oxygen mixture inhalation leads to the postoperative pain level reduction and increases the pain threshold in oncological patients.